T[he]{.smallcaps} zinc finger protein ZPR1 is located in the cytoplasm of quiescent mammalian cells (Galcheva- Gargova et al., 1996). Treatment with mitogens, including epidermal growth factor (EGF), causes the redistribution of ZPR1 from the cytoplasm to the nucleus ([@B12]). The function of ZPR1 in the nucleus has not been defined. However, the nuclear redistribution of ZPR1 in proliferating cells suggests that this protein may act as a signaling molecule that communicates mitogenic signals from the cytoplasm to the nucleus.

The mechanism of cytoplasmic retention of ZPR1 in quiescent cells is unclear. ZPR1 binds to a group of tyrosine kinase receptors, including the EGF and platelet-derived growth factor receptors ([@B12]). The binding of ZPR1 to these receptors is blocked after mitogen stimulation ([@B12]). It is therefore possible that ZPR1 may be sequestered in the cytoplasm by receptors in quiescent cells and that the mitogen-stimulated release of ZPR1 from these receptors may trigger the accumulation of ZPR1 in the nucleus. Although this is a plausible hypothesis, it appears that this possible mechanism represents an oversimplification of the processes that control the subcellular localization of ZPR1. First, it is unclear whether the relative abundance of receptors and ZPR1 is sufficient to account for the cytoplasmic sequestration of ZPR1 in quiescent cells. Second, ZPR1 lacks an obvious nuclear localization sequence that could direct nuclear accumulation when ZPR1 is released from receptor complexes. Third, in the present study, we find that the nuclear localization of ZPR1 is regulated in cells that lack tyrosine kinase receptors. These considerations suggest that the interaction of ZPR1 with other biomolecules may contribute to the regulation of the subcellular distribution of ZPR1.

Although it is known that ZPR1 binds to cell surface receptor molecules in quiescent cells, it is not established whether the effect of mitogens to inhibit the ZPR1/receptor interaction represents the formation of a novel ZPR1 complex with a different protein. The purpose of the study described in this report was to identify a protein that interacts with ZPR1 after treatment of cells with mitogens. This study was facilitated by the identification of ZPR1 homologues in mammals and yeast.

We report that ZPR1 binds to eukaryotic translation elongation factor-1α (eEF-1α).^1^ EGF stimulation of mammalian cells triggers the formation ZPR1/eEF-1α complexes and the translocation of both ZPR1 and eEF-1α from the cytoplasm to the nucleus. Similarly, in the yeast *S*. *cerevisiae*, ZPR1 redistributes between the cytoplasm and the nucleus in response to nutrient stimulation. Disruption of the *ZPR1* gene is lethal in *S*. *cerevisiae*. Deletion analysis demonstrated that ZPR1 can be divided into two functional domains. The NH~2~-terminal region of ZPR1 is required for normal growth whereas the COOH-terminal region is essential for viability. Disruption of the binding between ZPR1 and eEF-1α by mutational analysis caused the accumulation of cells in the G2/M phase of the cell cycle and defective growth. Reconstitution of the ZPR1 interaction with eEF-1α by inter-allelic complementation restored normal growth. These data establish a role for the formation of nuclear ZPR1/eEF-1α complexes in the normal growth of proliferating cells.

Previous studies have demonstrated that eEF-1α plays a pivotal role in protein biosynthesis ([@B19]). In addition, eEF-1α is known to be involved in diverse cellular processes, including embryogenesis ([@B16]), senescence ([@B23]), oncogenic transformation ([@B28]), cell proliferation ([@B22]), and organization of the cytoskeleton ([@B9]; [@B11]). eEF-1α is present mainly in the cytoplasm of cells ([@B11]; [@B18]), but a small population of eEF-1α molecules has been previously identified in the nucleus ([@B8]; [@B14]; Barberse et al., 1995; [@B3]; [@B22]). Recently, eEF-1α was shown to bind viral RNA ([@B4]) and RNA polymerases ([@B5]; [@B10]).

The involvement of eEF-1α in nuclear processes remains to be established. The results of the present study suggest that the physiological functions of eEF-1α in the nucleus may include complex formation with ZPR1 in mitogen-treated cells.

Materials and Methods {#MaterialsMethods}
=====================

Preparation of Recombinant Plasmids and Proteins
------------------------------------------------

The yeast *ZPR1* gene was isolated by screening an *S*. *cerevisiae* genomic library (prepared by [@B20]) using colony screening. A 300-bp fragment, amplified using the polymerase chain reaction (PCR), from the right arm of chromosome VII of *S*. *cerevisiae* was used for preparing the \[^32^P\]labeled probe for hybridization (Prime-It II; Stratagene, La Jolla, CA). Positive clones were examined by automated sequencing (model 373A; Applied Biosystems, Foster City, CA). The *S*. *pombe zpr1* ^+^ gene was isolated using a similar procedure ([@B13]). Subsequently, the open reading frame encoding *S*. *cerevisiae* ZPR1 (YGR211w) was identified in the *S*. *cerevisiae* genome (GenBank/EMBL/ DDBJ accession number [Z72996](Z72996)). The nucleotide sequence of the cloned *ZPR1* gene and YGR211w were identical. Standard recombinant DNA techniques were used to construct fusion proteins. The coding region of *S*. *cerevisiae ZPR1* (c*ZPR1*) was amplified by PCR with the c*ZPR1* genomic clone (pLG1) as the template and was subcloned in the plasmid pBS (Stratagene) as an XhoI fragment at the SalI site (pLG2). This c*ZPR1* fragment was cloned as an XhoI (blunt-ended)-EcoRI fragment (from pLG2) in pGEX-3X (Pharmacia Biotech, Piscataway, NJ) at the SmaI/ EcoRI sites. Full-length (wild-type) and truncated c*ZPR1*, amplified by PCR, were cloned in pCAL-n (Stratagene) and p413ADH (American Type Culture Collection, Rockville, MD) expression vectors at the SmaI/ EcoRI sites. Mouse *ZPR1* (m*ZPR1*), full-length and truncated fragments amplified by PCR, were cloned in pCAL-n at the EcoRI/XhoI sites. *S*. *pombe ZPR1* (p*ZPR1*) was PCR amplified and cloned in pGEX-3X at the BamHI/EcoRI sites. Mutant green fluorescent protein (GFP) (S65T, V163A; Anderson et al., 1996) was PCR amplified and cloned in p413 ADH at the SmaI/EcoRI sites to create the plasmid pMM48. A c*ZPR1* fragment (BglII-SmaI) amplified by PCR was cloned in pMM48 at the BamHI/SmaI sites to create the plasmid pMM49. The *S*. *cerevisiae* gene encoding translation elongation factor eEF-1α (*TEF1*) was amplified by PCR using genomic DNA as the template and was cloned into pGEX-5X-1 (Pharmacia Biotech) at the BamHI site. In-frame deletions were prepared using standard PCR-based procedures. The plasmids used in this study are summarized in Table [I](#TI){ref-type="table"}.

Recombinant plasmids that express fusion proteins with calmodulin-binding protein (CBP) and glutathione-S-transferase (GST) were expressed in BL21 (DE3) bacteria and BL21 bacteria, respectively. The fusion proteins were induced with 1 mM IPTG for 2 h at 30°C and were purified by affinity chromatography.

Disruption of the ZPR1 Gene
---------------------------

Yeast were manipulated according to standard procedures. The diploid strain (MY2) heterozygous for the *ZPR1* gene disruption was constructed using established techniques (Rothstein, 1993). The recombinant plasmid pMM6 was prepared by inserting two fragments of the c*ZPR1* gene (−785 bp to −10 bp and +970 bp to +1,471 bp) flanking the *LEU2* gene in the plasmid pRS405 ([@B24]). The ScaI-SpeI fragment from pMM6 containing the disrupted c*ZPR1* gene was transformed into the diploid yeast strain CY246 (obtained from C.L. Peterson, University of Massachusetts Medical School, Worcester, MA). Southern blots of the Leu^+^ transformants identified colonies heterozygous for the c*ZPR1* disruption. The heterozygote MY2 was sporulated and tetrads were dissected. The spores showed 2:2 segregation of viability and none of the viable spores were Leu^+^, indicating that the disruption of the c*ZPR1* gene was lethal. To isolate haploid yeast with the c*ZPR1* disrupted gene (*zpr1:: LEU2*), yeast strain MY2 (diploid) was transformed with the plasmid pMM13 (*ZPR1* under control of the *GAL* promoter on a *URA* ^+^ plasmid), sporulated, and then tetrads were dissected. Leu^+^ Ura^+^ haploid cells (*zpr1::LEU2*) complemented with wild-type c*ZPR1* on plasmid pMM13 were selected and designated as strain MY7. Mutant c*ZPR1* genes were introduced into strain MY7 by plasmid shuffling ([@B25]) using 5′-fluoroorotic acid (Toronto Research Chemicals, North York, Ontario, Canada). Yeast strains with wild-type and mutant c*ZPR1* are listed in Table [II](#TII){ref-type="table"}.

Mammalian Cell Culture
----------------------

COS-7 and A431 cells were maintained in Dulbecco\'s modified Eagle\'s medium, 2 mM glutamine, 100 U/ml penicillin and 100 U/ml streptomycin supplemented with 10% heat-inactivated fetal bovine serum (COS-7 cells) or 5% calf serum (A431 cells) (Life Technologies, Gaithersburg, MD). The cells were grown at 37°C in a humidified atmosphere with 5% CO~2~. Transfection with the plasmid pCDNA3-Flag-m*ZPR1* ([@B12]) was performed using Lipofectamine (Life Technologies) according to the manufacturer\'s instructions. A431 cells were grown to 50--60% confluence and starved in serum-free medium for 24 h. The cells were treated with 100 nM EGF or PMA for 5--60 min at 37°C.

Binding Assays
--------------

Binding assays were performed using CBP and GST fusions with \[^35^S\]methionine-labeled and -unlabeled cell lysates. The cell extracts were prepared with lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10 mM β-mercaptoethanol, 1.0 mM MgCl~2~, 1.0 mM CaCl~2~, 1.0 mM imidazole, 0.1% Triton X-100, 1.0 mM PMSF, 1.0 mM benzamidine, 1 mM sodium orthovanadate, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 10 μg/ml bestatin, 10 μg/ml antipain, 1.0 μg/ml pepstatin A, and 1.0 μg/ml chymostatin). CBP and GST fusions (5 μg) were immobilized on calmodulin affinity resin (Stratagene) and glutathione agarose beads (Pharmacia Biotech), respectively. The beads (20 μl) were washed twice at 4°C and incubated with cell extracts (300--500 μg protein) for 2 h in 500 μl lysis buffer at 4°C and then washed three times. The beads were boiled with Laemmli sample buffer for 3 min, centrifuged, and then the supernatant was examined by SDS-PAGE.

Mass Spectroscopy
-----------------

A 50-kD ZPR1 binding protein was purified from human A431 epidermoid carcinoma cells and *S*. *cerevisiae* strain L40 by affinity chromatography using immobilized CBP-ZPR1 (residues 1--268). Bound proteins were separated by SDS-PAGE and electrotransferred to a polyvinylene difluoride (PVDF) membrane (Applied Biosystems). The membrane was stained with Ponceau S and the 50-kD protein was excised, rinsed with water, and then air dried. The protein was digested with [l-]{.smallcaps}tosylamido-2-phenyl ethyl chloromethyl ketone-treated trypsin and subjected to mass spectroscopic analysis using the matrix-assisted laser desorption ionization with time of flight (MALDI-TOF) technique. Masses of the polypeptides obtained were compared with the MS-Fit data base (Ludwig Institute for Cancer Research and University College London mass spectroscopy facility, London, UK).

Immunoprecipitation and Immunoblotting
--------------------------------------

Cell extracts prepared using Triton lysis buffer (20 mM Tris-HCl, pH 7.4, 137 mM NaCl, 2 mM EDTA, 25 mM β-glycerophosphate, 2 mM sodium pyrophosphate, 1% Triton X-100, 10% glycerol, 1 mM PMSF, 1 mM sodium orthovanadate, 10 μg/ml leupeptin, and 10 μg/ml aprotinin) were used for immunoprecipitation studies. Antibodies to mouse ZPR1 ([@B12]), eEF-1α (Upstate Biotechnology, Lake Placid, NY) and Flag (M2; Eastman-Kodak, Rochester, NY) were prebound to 20 μl of protein A--Sepharose (Pharmacia Biotech). The beads were incubated with cell lysate for 2 h, washed three times, and then boiled with Laemmli sample buffer before gel electrophoresis. Bound proteins separated by SDS-PAGE (10%) were electrotransferred to PVDF membranes (0.45 μm; Millipore, Waters Chromatography, Milford, MA). Antibody incubations were carried out in Tris-buffered saline with 0.5% Tween-20 and 20% horse serum. The rabbit anti-ZPR1 and mouse anti--eEF-1α antibodies were diluted 1:400 and 1:1,000, respectively. HRP-conjugated donkey anti--rabbit IgG and sheep anti--mouse IgG (1:5,000) secondary antibodies were detected by enhanced chemiluminescence (Amersham International, Little Chalfont, UK).

Fluorescence Microscopy
-----------------------

A431 cells were cultured on glass coverslips coated with poly-[l]{.smallcaps}-lysine. The cells were incubated in serum-free medium for 24 h, starved, and then treated with 100 nM EGF or PMA at 37°C for 15 min. Coverslips were rinsed with phosphate-buffered saline (PBS) and then briefly with chilled methanol. The cells were fixed at −20°C with methanol for 5 min, and then with acetone for 2 min. The coverslips were blocked with 10% horse serum in PBS with 0.5% Tween-20 (PBS-T) for 30 min at 25°C in Coplin jars and then incubated with primary antibodies for 1 h at 25°C. The rabbit polyclonal antibody to ZPR1 has been described ([@B12]). The mouse monoclonal antibody to eEF-1α was purchased from Upstate Biotechnology. The cells were washed with PBS-T (0.2% Tween-20) three times and incubated with conjugated secondary antibodies (goat cyanine \[Cy3\]-labeled anti-rabbit IgG and goat fluorescein \[FITC\]-labeled anti-mouse IgG; Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 h and washed three times with PBS-T (0.2% Tween-20). Coverslips were mounted on slides using Vectashield (Vector Laboratories, Burlingame, CA) and examined by double-label immunofluorescence microscopy using a conventional microscope (Carl Zeiss Inc., Thornwood, NY).

Haploid yeast cells with the disrupted *zpr1::LEU2* gene were transformed with plasmids expressing wild-type cZPR1, mutated cZPR1, or cZPR1 fusion proteins with GFP. Cells were grown in synthetic media with glucose (2%). Log-phase cultures were diluted (0.5 OD~600~) and starved in glucose-free medium for 12 h at 30°C. Glucose (2%) was added and the cells were incubated at 30°C for 2 h. The cells were harvested and stained with 4′6-diamidino-2-phenylindole (DAPI). The GFP and DAPI fluorescence was examined by conventional microscopy (Carl Zeiss Inc.). Image analysis was performed using the computer software NIH Image (v 1.61/PPC; Bethesda, MD).

Flow Cytometry
--------------

Samples were prepared for flow cytometry ([@B17]). Cells (10^6^) were pelleted, washed twice with PBS, resuspended in 100 μl PBS, and then added dropwise into 70% ethanol (1.5 ml) with vortexing. The cells were fixed overnight in 70% ethanol at 4°C, washed with PBS, and then digested with 1 mg/ml RNase in 50 mM Tris-HCl, pH 8.0, for 1 h at 37°C followed by 5 mg/ml pepsin in 55 mM HCl for 30 min at 37°C. The cells were washed with PBS, stained with propidium iodide, and then analyzed.

Results {#Results}
=======

The Zinc Finger Protein ZPR1 Is Conserved in Mammals and Yeast
--------------------------------------------------------------

Homologues of the mammalian zinc finger protein ZPR1 were identified and cloned from the yeast *S*. *cerevisiae* and *Schizosaccharomyces pombe*. The sequence of the mouse, *S*. *cerevisiae* and *S*. *pombe* ZPR1 proteins was deduced from the nucleotide sequence of DNA clones (Fig. [1](#F1){ref-type="fig"} *A*). Comparison of these ZPR1 proteins indicates a conserved structure including two similar zinc fingers (ZnF1 and ZnF2) and similar regions after each zinc finger (Fig. [1](#F1){ref-type="fig"} *B*, *A* and *B*). The mouse ZPR1 (mZPR1) protein is 46% identical and 72% similar to *S*. *cerevisiae* ZPR1 (cZPR1) and 43% identical and 70% similar to *S*. *pombe* ZPR1 (pZPR1). The two yeast proteins are 55% identical and 78% similar. The high level of homology between yeast and mammalian ZPR1 suggests that the overall structure of the protein is conserved between lower and higher eukaryotes.

ZPR1 Is an Essential Gene in S. cerevisiae
------------------------------------------

We examined whether the gene encoding c*ZPR1* was essential for cell viability in *S*. *cerevisiae*. A DNA fragment containing the c*ZPR1* gene disrupted by the *LEU2* gene (Fig. [2](#F2){ref-type="fig"} *A*) was transformed into the diploid yeast strain CY246. Colonies were selected on plates lacking leucine and the disruption of one genomic copy of c*ZPR1* was confirmed by Southern blot analysis (Fig. [2](#F2){ref-type="fig"} *B*). The diploid yeast strain MY2, which is heterozygous for wild-type c*ZPR1* (*ZPR1*/*zpr1::LEU2*), was sporulated and the tetrads were dissected. In all tetrads analyzed, the viable progeny segregated 2:2, and none of the surviving spores were Leu^+^ (disrupted for c*ZPR1*). These data indicate that the c*ZPR1* gene is essential for viability (Fig. [2](#F2){ref-type="fig"} *C*). To establish that the loss of viability was due to the disruption of the c*ZPR1* gene, we complemented haploid yeast with the disrupted c*ZPR1* gene (*zpr1::LEU2*) using a plasmid expressing wild-type c*ZPR1*. These data demonstrated that the c*ZPR1* gene was essential for viability in *S*. *cerevisiae*.

Identification of eEF-1α as a ZPR1-binding Protein
--------------------------------------------------

To study the interaction of ZPR1 with other proteins, we performed in vitro binding assays using \[^35^S\]methionine human A431 epidermoid carcinoma cell extracts and immobilized GST--ZPR1 fusion proteins. As expected, the mouse ZPR1 protein bound to the 180-kD EGF receptor (Fig. [3](#F3){ref-type="fig"} *A*). In addition, several other \[^35^S\]methionine proteins were observed to bind ZPR1. In particular, a 50-kD protein was prominently detected in binding assays using mouse, *S*. *cerevisiae* and *S*. *pombe* ZPR1 proteins (Fig. [3](#F3){ref-type="fig"} *A*). Similar results were obtained in binding assays using \[^35^S\]methionine extracts prepared from COS-7, CHO, and *S*. *cerevisiae* (strain L40) cells (data not shown). These data indicate that the yeast and mammalian ZPR1 proteins may have similar biochemical properties, including interaction with a 50-kD protein.

Deletion analysis of mouse ZPR1 using \[^35^S\]methionine cell extracts demonstrated that an NH~2~-terminal mZPR1 fragment (ZnF1-A; residues 1--268) was sufficient for binding the 50-kD protein (data not shown). This fragment of mZPR1 was used to isolate the 50-kD protein from human (A431) and *S*. *cerevisiae* (L40) cell extracts by affinity chromatography. The bound proteins were resolved by SDS-PAGE and electrotransferred onto a PVDF membrane. The 50-kD protein was digested with [l]{.smallcaps}-tosylamido-2-phenyl ethyl chloromethyl ketone-treated trypsin and examined by mass spectroscopy using the MALDI-TOF technique. A comparison of the masses of the polypeptides obtained with the MS-Fit data base led to the identification of the 50-kD protein as eEF-1α (Table [III](#TIII){ref-type="table"}).

To confirm the identification of the 50-kD protein as eEF-1α, we examined the proteins that bound to mZPR1 by Western blot analysis using an antibody to eEF-1α. Immobilized recombinant mZPR1 was found to bind eEF-1α (Fig. [3](#F3){ref-type="fig"} *B*, lane *8*). Similarly, immobilized recombinant eEF-1α bound to mZPR1 (Fig. [3](#F3){ref-type="fig"} *C*). Deletion analysis demonstrated that the NH~2~-terminal region of mZPR1 was sufficient for binding eEF-1α (Fig. [3](#F3){ref-type="fig"} *B*). Deletion analysis of eEF-1α demonstrated that the NH~2~-terminal region (residues 1--300) was required for binding ZPR1 (data not shown). To test whether ZPR1 and eEF-1α bind directly, we performed in vitro assays using the two purified recombinant proteins. This analysis demonstrated that eEF-1α directly binds to cZPR1 (Fig. [3](#F3){ref-type="fig"} *D*).

Interaction of eEF-1α and ZPR1 In Vivo
--------------------------------------

To test whether eEF-1α and ZPR1 may interact in vivo, we performed coimmunoprecipitation analysis. Epitope-tagged mZPR1 was immunoprecipitated from serum-treated COS-7 cells and the presence of eEF-1α in the immunoprecipitates was examined by Western blot analysis. Fig. [4](#F4){ref-type="fig"} *A* shows that eEF-1α was coimmunoprecipitated with ZPR1. Control experiments using cells that did not express epitope-tagged mZPR1 demonstrated no coimmunoprecipitation of eEF-1α. These data indicate that ZPR1 and eEF-1α may interact in vivo.

ZPR1 has been shown to bind the EGF receptor in quiescent cells and to be released from the receptor upon treatment with EGF ([@B12]). EGF may therefore regulate the interaction of ZPR1 with eEF-1α. To examine the effect of EGF, we starved A431 cells in serum-free medium for 24 h and then treated the cells with 100 nM EGF. eEF-1α was immunoprecipitated and the presence of ZPR1 was detected by Western blot analysis. Coimmunoprecipitation of ZPR1 with eEF-1α was detected in the EGF-treated cells, but not in the serum-starved cells (Fig. [4](#F4){ref-type="fig"} *B*). The amount of coimmunoprecipitated ZPR1 was sustained during longer periods of treatment with EGF (Fig. [4](#F4){ref-type="fig"} *C*). These data indicate that EGF induces an interaction between ZPR1 and eEF-1α. To test whether this interaction between ZPR1 and eEF-1α can be induced by other stimuli, we studied the effect of serum. Treatment of serum-starved cells with fetal calf serum (10%) resulted in the coimmunoprecipitation of ZPR1 with eEF-1α (Fig. [4](#F4){ref-type="fig"}, *B* and *C*). Based on these observations, we propose that growth signals in mitogen-activated cells may induce the formation of eEF-1α/ZPR1 complexes in vivo. Specificity in the formation of the eEF-1α/ ZPR1 complex was established by the observation that treatment of the cells with the tumor promoter phorbol 12-myristate 13-acetate (PMA) did not cause coimmunoprecipitation of ZPR1 with eEF-1α (Fig. [4](#F4){ref-type="fig"} *B*).

Redistribution of ZPR1 and eEF-1α to the Nucleus of Mitogen-activated Mammalian Cells
-------------------------------------------------------------------------------------

We examined the subcellular localization of ZPR1 and eEF-1α in mammalian cells by double-label immunofluorescence microscopy. Consistent with previous studies ([@B12]) we observed that ZPR1 (*red*) redistributed from the cytoplasm to the nucleus upon EGF stimulation of serum-starved cells (Fig. [5](#F5){ref-type="fig"}). eEF-1α is an abundant protein that is present mainly in the cytoplasm of cells ([@B11]). Fig. [5](#F5){ref-type="fig"} shows the effect of EGF treatment on the subcellular distribution of eEF-1α (*green*). In serum-starved cells, eEF-1α was present in the cytoplasm. Upon treatment with EGF, a fraction of the eEF-1α molecules was observed to redistribute from the cytoplasm to the nucleus. The distribution of eEF-1α and ZPR1 in the nucleus after treatment of cells with EGF was similar, as represented by yellow fluorescence in the merged images of ZPR1 and eEF-1α (Fig. [5](#F5){ref-type="fig"}). Similar results were obtained upon treatment of serum-starved cells with 10% calf serum (data not shown). Quantitative analysis of the fluorescence images demonstrated that ZPR1 was ∼98% cytoplasmic in serum-starved cells and was ∼96% nuclear in EGF-treated cells. Similar analysis demonstrated that eEF-1α was not detected in the nucleus of serum-starved cells and that ∼5% of the total eEF-1α was located in the nucleus after stimulation with EGF. These data indicate that both ZPR1 and eEF-1α are located in the nucleus of mitogen-treated cells. The punctate distribution of ZPR1 in the nucleus was previously demonstrated to correspond to an accumulation within nucleoli ([@B12]). This nucleolar accumulation is characterized by colocalization of ZPR1 with fibrillarin and RNA polymerase I, but not with splicing factor SC35 or p80 coilin ([@B13]).

We studied the effect of PMA on the subcellular distribution of eEF-1α and ZPR1 to confirm the specificity of the interaction between eEF-1α and ZPR1 in the response to extracellular stimulation. PMA is known to induce the phosphorylation of eEF-1α by activating protein kinase C ([@B30]). However, PMA did not cause punctate nuclear accumulation of eEF-1α or ZPR1 (Fig. [5](#F5){ref-type="fig"}). These data are consistent with the results of coimmunoprecipitation analysis where treatment with PMA did not induce the formation of ZPR1/eEF-1α complexes (Fig. [4](#F4){ref-type="fig"} *B*). We conclude that ZPR1 responds to selective extracellular stimuli.

Nuclear Redistribution of ZPR1 in Yeast
---------------------------------------

To study the localization of cZPR1 in the yeast *S*. *cerevisiae*, a recombinant c*ZPR1--GFP* fusion gene was constructed. The c*ZPR1--GFP* gene complemented the loss of viability of yeast with the disrupted *zpr1::LEU2* gene. These haploid yeast expressing the cZPR1--GFP fusion protein were examined by fluorescence microscopy. Control experiments demonstrated that GFP was sequestered in the vacuole of yeast expressing GFP alone (data not shown). Fig. [6](#F6){ref-type="fig"} shows that the cZPR1--GFP fusion protein (*green*) was present mainly in the nucleus of *S*. *cerevisiae* (*CONTROL*). Starvation of the yeast in glucose-free medium caused the redistribution of cZPR1 from the nucleus to the cytoplasm (Fig. [6](#F6){ref-type="fig"}). Readdition of glucose to the starved cells induced the translocation of cZPR1 from the cytoplasm to the nucleus. The localization and redistribution of ZPR1 in response to nutrients in *S*. *cerevisiae* appears to be similar to that observed in starved and mitogen-treated mammalian cells. Therefore, it is possible that cZPR1 may function as a signaling molecule in *S*. *cerevisiae* that responds to proliferation signals.

Identification of Mutant ZPR1 Molecules That Fail to Interact with eEF-1α
-------------------------------------------------------------------------

To examine the interaction of ZPR1 with eEF-1α, we performed deletion analysis of cZPR1. Studies using NH~2~-terminal (NT) and COOH-terminal (CT) fragments of cZPR1 demonstrated that the eEF-1α--binding site was located in the NH~2~-terminal region of cZPR1 (residues 1--261) (Fig. [7](#F7){ref-type="fig"}, *A* and *B*). We constructed a series of COOH-terminal truncated mutants of the NT fragment of cZPR1. Binding assays indicated that cZPR1 residues 202--261 were required for the interaction of eEF-1α with cZPR1 (data not shown). Subsequently, a series of in-frame deletion mutants of full-length cZPR1 (D1-D4) was prepared (Fig. [7](#F7){ref-type="fig"} *A*). These internal deletion mutants were expressed as CBP fusions in bacteria and purified. The binding of eEF-1α to these cZPR1 proteins was detected by immunoblot analysis. The in-frame deletions D1 (residues 222-- 241) and D2 (residues 222--261) had no effect on eEF-1α binding, whereas deletions D3 (residues 202--241) and D4 (residues 202--261) eliminated the binding of eEF-1α to cZPR1 (Fig. [7](#F7){ref-type="fig"} *C*). These data suggest that a sequence required for eEF-1α binding is present in the D3 region (residues 202--241) of cZPR1 (Fig. [7](#F7){ref-type="fig"} *A*). To further delineate the cZPR1 sequence required for the binding of eEF-1α, the smaller in-frame deletion mutant D5 (residues 202-- 221) was prepared and tested for eEF-1α binding. Immunoblot analysis demonstrated that the cZPR1 deletion mutant D5 did not bind eEF-1α (Fig. [7](#F7){ref-type="fig"} *D*). Therefore, the 20-amino acid region D5 (residues 202--221) was required to be present in full-length and truncated ZPR1 for eEF-1α binding. This region is located within the A-domain of the cZPR1 protein and is conserved in mouse, *S*. *cerevisiae* and *S*. *pombe* (Fig. [7](#F7){ref-type="fig"} *A*).

Mutational Analysis of ZPR1 Function
------------------------------------

We examined the effect of cZPR1 mutations that disrupt eEF-1α binding on the viability of *S*. *cerevisiae*. The in-frame deletion mutants D1, D2, D3, D4, and D5 complemented the loss of viability caused by the disruption of the c*ZPR1* gene in *S*. *cerevisiae* (Table [IV](#TIV){ref-type="table"}). These data indicate that deletion of sequences required for eEF-1α binding did not affect the essential role of ZPR1 required for viability. Therefore, the binding of cZPR1 to eEF-1α was not required for viability of *S*. *cerevisiae*.

We performed deletion analysis to identify the region of cZPR1 that was required for yeast viability. Expression of an NT fragment of cZPR1 (residues 1--261), which includes the first zinc finger and the region required for interaction with eEF-1α, did not confer viability (Table [IV](#TIV){ref-type="table"}). In contrast, expression of a CT fragment of cZPR1 (residues 262--486), which includes the second zinc finger and does not interact with eEF-1α, was able to confer viability (Table [IV](#TIV){ref-type="table"}). These data demonstrate that the functions of cZPR1 to bind eEF-1α and to confer viability are encoded within separate regions of the c*ZPR1* gene. eEF-1α binding requires the NT fragment of cZPR1 and viability requires the CT fragment of cZPR1.

To further examine the sequences present in the CT fragment of cZPR1 that are required for viability, we examined the effect of mutations in the cZPR1 zinc fingers. The zinc fingers were disrupted by replacing two of the Cys residues with Ala. Mutation of zinc finger 1 (located in the NT fragment of cZPR1) complemented the loss of viability caused by disruption of the ZPR1 gene. In contrast, mutation of the second zinc finger (present in the CT region of cZPR1) did not confer viability in this assay (Table [IV](#TIV){ref-type="table"}). These data indicate that the sequences located in CT that are required for viability include the second zinc finger.

Interaction of ZPR1 with eEF-1α Is Required for Normal Growth
-------------------------------------------------------------

The interaction of cZPR1 with eEF-1α did not appear to be essential for viability of the yeast *S*. *cerevisiae* (Table [IV](#TIV){ref-type="table"}). However, ZPR1 and eEF-1α interact in response to extracellular growth stimuli (Fig. [4](#F4){ref-type="fig"}, *B* and *C*). Therefore, it was possible that this interaction may play a role in the normal process of cellular proliferation. To examine the function of the ZPR1/eEF-1α complex in cellular growth, we investigated the effect of cZPR1 mutations that disrupt eEF-1α binding on the growth of *S*. *cerevisiae*. Control experiments demonstrated that the cZPR1 mutants D1 and D2, which bind eEF-1α, exhibited no growth defect (Fig. [8](#F8){ref-type="fig"} *A*). In contrast, the yeast strains (Table [II](#TII){ref-type="table"}) expressing mutant cZPR1 (D3, D5, and CT) proteins that do not bind eEF-1α (Table [IV](#TIV){ref-type="table"}) were found to grow at least 20-fold slower than yeast expressing wild-type cZPR1 (Fig. [8](#F8){ref-type="fig"}, *A* and *B*).

The morphology of the yeast strains expressing wild-type and mutant cZPR1 proteins was examined by light microscopy. Fig. [8](#F8){ref-type="fig"} *C* shows images of yeast expressing wild-type cZPR1 or mutant D5 cZPR1 that does not bind eEF-1α. Cells with mutant cZPR1 (D5) are larger and grow in chain-like clusters. The failure of the cells to separate and their larger size suggest that these slow-growing yeast may accumulate in the G2/M phase of the cell cycle. These cells were therefore examined for DNA content by flow cytometry. Fig. [8](#F8){ref-type="fig"} *C* shows that the wild-type cells are distributed between the G1 and G2 phases of the cell cycle, corresponding to 1N and 2N DNA content, respectively (Fig. [8](#F8){ref-type="fig"} *C*). In contrast, the majority of the mutant yeast cells contained 2N DNA (Fig. [8](#F8){ref-type="fig"} *D*), consistent with an accumulation in the G2/M phase of the cell cycle (Fig. [8](#F8){ref-type="fig"} *C*). These data suggest that the interaction of cZPR1 with eEF-1α may be required for normal cell cycle progression.

To examine whether the absence of binding to eEF-1α is relevant to the defective growth of yeast strains that express mutant cZPR1 molecules (D3, D5, and CT), we performed an interallelic complementation assay. The NT fragment of cZPR1 binds eEF-1α, but is not sufficient for viability. However, the expression of the NT fragment of cZPR1 in the D3, D5, and CT mutant ZPR1 yeast strains restored normal proliferation (Fig. [8](#F8){ref-type="fig"}, *A* and *B*). To confirm that the restoration of normal growth is due to the interaction of ZPR1 with eEF-1α, a yeast strain expressing the CT fragment was transformed with a plasmid expressing the NT (ΔD5) fragment of cZPR1 which does not bind eEF-1α. Expression of NT (ΔD5) did not restore the growth of the yeast complemented with the CT fragment of cZPR1 (Fig. [8](#F8){ref-type="fig"} *B*). These data are consistent with the hypothesis that the interaction of cZPR1 with eEF-1α was required for the normal growth of yeast. The specificity of the D5 mutation to cause reduced growth was tested by comparison with the effect of mutation of the first zinc finger of cZPR1 (replacement of two of the Cys residues with Ala). Mutation of the first zinc finger caused slow growth that was not associated with accumulation at the G2/M phase of the cell cycle (data not shown). Thus, the G2/M accumulation caused by the D5 mutation does not represent a nonspecific consequence of defects in cZPR1 function.

To further examine the effect of the NT fragment of cZPR1 to restore the normal growth of yeast that express the D5 mutant cZPR1, we studied the effect of cZPR1 mutations on the subcellular localization of cZPR1 in *S*. *cerevisiae*. The GFP-labeled NT and CT fragments of cZPR1 (NT--GFP and CT--GFP), like wild-type cZPR1-GFP, were found to accumulate within the nucleus (Fig. [8](#F8){ref-type="fig"} *E*). The distribution of the D5 mutant cZPR1-GFP (D5--GFP) was similar to wild-type cZPR1--GFP (Fig. [8](#F8){ref-type="fig"} *E*). Therefore, deletion of the D5 region did not affect the nuclear distribution of cZPR1 in growing cells. These data demonstrate that cZPR1 can accumulate in the nucleus independently of eEF-1α.

Discussion {#Discussion}
==========

ZPR1 Is Conserved in Mammals and Yeast
--------------------------------------

ZPR1 is a zinc finger protein that was initially identified in mammals ([@B12]). This protein contains two zinc fingers with the primary structure: Cys-Xaa~2~-Cys-Xaa~25~-Cys-Xaa~2~-Cys. Atomic absorption spectroscopy confirmed the presence of two zinc atoms in each ZPR1 molecule ([@B12]). Here we demonstrate that the ZPR1 protein is conserved in budding yeast (*S*. *cerevisiae*) and fission yeast (*S*. *pombe*). A homologue of ZPR1 was also identified in the nematode *Caenorhabditis elegans* by searching the GenBank database ([@B32]; GenBank/EMBL/DDBJ accession number [AF022981](AF022981)) using the BLAST File Server (National Center for Biotechnology Information, Bethesda, MD). The conserved structure of the ZPR1 proteins from these diverse species indicates that the ZPR1 protein may have similar functions in higher and lower eukaryotes.

To examine the function of ZPR1 in eukaryotic cells, we studied its role in the yeast *S*. *cerevisiae*. Gene disruption experiments demonstrated that ZPR1 was essential for viability in *S*. *cerevisiae*. Deletion analysis and genetic complementation assays demonstrated that the COOH-terminal region of ZPR1 (including the second zinc finger) was required for viability. In contrast, the NH~2~-terminal region of ZPR1 (including the first zinc finger) was dispensable for yeast viability.

The requirement for the COOH-terminal region of cZPR1 for yeast viability may have evolutionary significance. Prokaryotic homologues of ZPR1 have not been described. However, prokaryotes may contain a homologue of the COOH-terminal region of ZPR1. Conceptual translation of the genomic sequences of several bacteria, including *Escherichia coli* ([@B29]; GenBank/ EMBL/DDBJ accession number [P25538](P25538)), *Synechococcus sp*. ([@B27]; GenBank/EMBL/DDBJ accession number [P46227](P46227)), *Methanococcus jannaschii* ([@B6]; GenBank/EMBL/DDBJ accession number O57950), *Archaeoglobus fulgidus* ([@B15]; GenBank/ EMBL/DDBJ accession number AE00150), and *Methanobacterium thermoautotrophicum* (Smith et al., 1997; GenBank/EMBL/DDBJ accession number [AE000936](AE000936)) indicates the presence of a conserved hypothetical protein with one zinc finger similar to the COOH-terminal region of ZPR1. Whether these hypothetical prokaryotic zinc finger proteins share functions that are similar to the eukaryotic ZPR1 proteins is presently unclear, but warrants further study.

Nuclear Redistribution of ZPR1 in Proliferating Cells
-----------------------------------------------------

The ZPR1 protein is located in the cytoplasm of quiescent mammalian cells and redistributes to the nucleus after treatment with mitogens ([@B12]). Immunofluorescence analysis demonstrated that the nuclear ZPR1 protein exhibited a punctate appearance. Double-label immunofluorescence microscopy demonstrated that nuclear ZPR1 colocalized with fibrillarin and RNA polymerase I, but not with the splicing factor SC35 or p80 coilin ([@B13]). The colocalization with fibrillarin and RNA polymerase I suggests that ZPR1 accumulates within nucleoli.

Although ZPR1 is known to redistribute between the cytoplasm and the nucleus in mammalian cells ([@B12]), it was unclear whether the subcellular localization of ZPR1 was regulated in yeast. Here we demonstrate that ZPR1 redistributes between the cytoplasm and the nucleus in the yeast *S*. *cerevisiae*. In proliferating yeast, the ZPR1 protein was located preferentially in the nucleus. In contrast, nutrient deprivation of yeast, like serum starvation of mammalian cells, caused the redistribution of ZPR1 from the nucleus to the cytoplasm. These data indicate that ZPR1 responds to proliferative signals in both mammals and yeast. Further studies are required to determine the mechanism of nuclear exclusion and nuclear accumulation in response to altered proliferative states.

Interaction of ZPR1 with eEF-1α in Mitogen-treated Cells
--------------------------------------------------------

The ZPR1 protein was found to bind eEF-1α. Coimmunoprecipitation analysis demonstrated that ZPR1 did not interact with eEF-1α in serum-starved mammalian cells. In contrast, treatment with EGF or serum caused rapid induction of ZPR1 complex formation with eEF-1α. Control studies demonstrated that the formation of ZPR1/eEF-1α complexes was selective because the treatment of cells with phorbol ester did not cause coimmunoprecipitation of eEF-1α and ZPR1. These data indicate that whereas ZPR1 interacts with cell surface receptors in quiescent cells ([@B12]), ZPR1 binds to eEF-1α after treatment of the cells with certain extracellular stimuli.

eEF-1α is preferentially located in the cytoplasm of cells ([@B11]; [@B18]). In contrast, ZPR1 is located in the nucleus of mitogen-activated cells ([@B12]). The cytoplasmic location of eEF-1α is incompatible with the evidence that nuclear ZPR1 in mitogen-activated cells forms complexes with eEF-1α. As eEF-1α is an abundant cellular protein, we considered the possibility that the population of eEF-1α molecules that form complexes with ZPR1 represents only a fraction of the total eEF-1α present within the cell. To test this hypothesis, we examined the nuclear accumulation of eEF-1α in serum-starved and EGF-treated cells. This analysis demonstrated that nuclear eEF-1α was not detected in starved cells, but was detected in EGF-treated cells. Interestingly, the nuclear eEF-1α exhibited a punctate immunofluorescence appearance that was similar to ZPR1. These data are consistent with the hypothesis that mitogen-treatment of cells caused the formation of nuclear complexes of ZPR1 with eEF-1α. Further evidence to support this interpretation was obtained from the observation that the treatment of cells with phorbol ester, which does not cause the formation of ZPR1/eEF-1α complexes, did not cause punctate nuclear localization of eEF-1α.

The preferential location of eEF-1α in the cytoplasm is established ([@B11]; [@B18]) and the presence of a nuclear subpopulation of eEF-1α has been described (Collig et al., 1994; [@B14]; Barberse et al., 1995; [@B3]; [@B22]). These two populations of eEF-1α may play different physiological roles. The results of this study demonstrate that nuclear eEF-1α includes complexes of eEF-1α with ZPR1 in proliferating cells. Previous studies of eEF-1α indicate that it can bind RNA ([@B4]) and that it interacts with RNA polymerase polymerases ([@B5]; [@B10]). One possible role of the nucleolar complex of eEF-1α with ZPR1 is to functionally interact, directly or indirectly, with RNA. The eEF-1α GTPase activity may contribute to this putative regulatory function of the ZPR1/eEF-1α complex.

Interaction of ZPR1 with eEF-1α Is Required for Normal Cellular Proliferation
-----------------------------------------------------------------------------

Deletion analysis demonstrated that a short segment of the NH~2~-terminal region of ZPR1 was required for the interaction of ZPR1 with eEF-1α. Since the COOH-terminal region of ZPR1 was sufficient for yeast viability, we conclude that the interaction of ZPR1 with eEF-1α is not required for viability. This conclusion was strongly supported by the observation that small in-frame deletions, which disrupt binding to eEF-1α, did not affect the ability of ZPR1 to confer viability. However, yeast strains expressing ZPR1 proteins that did not bind eEF-1α were found to exhibit slow growth, aberrant morphology, and to accumulate at the G2/M phase of the cell cycle. These data indicate that the interaction of ZPR1 with eEF-1α may be required for the normal proliferation of yeast. We tested this hypothesis by performing an interallelic complementation assay using an NH~2~-terminal fragment of ZPR1 which binds to eEF-1α, but is insufficient for viability. This fragment of ZPR1 complemented the defective growth of yeast strains that express ZPR1 proteins that do not bind eEF-1α. In contrast, deletion of sequences required for eEF-1α binding to the NH~2~-terminal fragment of ZPR1 (NT ΔD5) blocked the interallelic complementation. These data provide strong support for the hypothesis that the binding of ZPR1 to eEF-1α is required for normal cellular proliferation. Further studies are required to determine whether the ZPR1/eEF-1α complex is required for proliferation of mammalian cells. In addition, studies are required to establish the molecular mechanism of action of the ZPR1/eEF-1α complex in vivo.
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CBP

:   calmodulin-binding protein

CT

:   COOH-terminal region of ZPR1

cZPR1

:   *S*. *cerevisiae* ZPR1

DAPI

:   4′6-diamidino-2-phenylindole

eEF-1α

:   eukaryotic translation elongation factor-1α

GFP

:   green fluorescent protein

GST

:   glutathione-S-transferase

mZPR1

:   mouse ZPR1

NT

:   NH~2~-terminal region of ZPR1

PMA

:   phorbol 12-myristate 13-acetate

PVDF

:   polyvinylene difluoride

pZPR1

:   *S*. *pombe* ZPR1

###### 

Plasmids

  Plasmids      Description                                           Source
  ---------- -- -------------------------------------------------- -- ----------------------------------
  YCp50         *URA3*, *ARS1*, *CEN4*                                [@B20]
  pRS317        *LYS2*, *ARSH4*, *CEN6*                               [@B25]
  pRS405        *LEU2*                                                [@B24]
  pRS426        *URA3*, 2 μ                                           [@B7]
  p413ADH       *HIS3*, *ARSH4*, *CEN6* with *ADH* promoter           American Type Culture Collection
  pLG1          YCp50 with genomic c*ZPR1*                            This study
  pLG2          pBS with c*ZPR1*                                      This study
  pLP1          pGEX-3X with c*ZPR1*                                  This study
  pLP2          pGEX-5X-1 with *TEF1*                                 This study
  pLP3          pCAL-n with c*ZPR1*                                   This study
  pLP4          pCAL-n with m*ZPR1* (1--774)                          This study
  pLPNT         pCAL-n with c*ZPR1* (1--780)                          This study
  pLPCT         pCAL-n with c*ZPR1* (781--1,458)                      This study
  pLPD1         pCAL-n with c*ZPR1* Δ (664--723)                      This study
  pLPD2         pCAL-n with c*ZPR1* Δ (664--783)                      This study
  pLDP3         pCAL-n with c*ZPR1* Δ (604--723)                      This study
  pLDP4         pCAL-n with c*ZPR1* Δ (604--783)                      This study
  pLPD5         pCAL-n with c*ZPR1* Δ (604--663)                      This study
  pLC1          p413ADH with c*ZPR1*                                  This study
  pLCNT         p413ADH with c*ZPR1* (1--780)                         This study
  pLCCT         p413ADH with c*ZPR1* (781--1,458)                     This study
  pLCCT2        pRS317 with *ADH* promoter, c*ZPR1* (781--1,458)      This study
  pLCD1         p413ADH with c*ZPR1* Δ (664--723)                     This study
  pLCD2         p413ADH with c*ZPR1* Δ (664--783)                     This study
  pLCD3         p413ADH with c*ZPR1* Δ (604--723)                     This study
  pLCD4         p413ADH with c*ZPR1* Δ (604--783)                     This study
  pLCD5         p413ADH with c*ZPR1* Δ (604--663)                     This study
  pLCNT2        p413ADH with c*ZPR1* (1--780) Δ (604--663)            This study
  pLCG1         p413ADH with c*ZPR1* Δ (604--663), *GFP*              This study
  pLCG2         p413ADH with c*ZPR1* (1--780), *GFP*                  This study
  pLCG3         p413ADH with c*ZPR1* (781--1,485), *GFP*              This study
  pMM6          pRS405 with c*ZPR1* (−785 to −10), (970--1,471)       This study
  pMM13         pRS426 with *GAL* promoter, c*ZPR1*                   This study
  pMM29         p413ADH with c*ZPR1* (294, 297 C/A)                   This study
  pMM36         p413ADH with c*ZPR1* (54, 57 C/A)                     This study
  pMM38         pRS317 with *ADH* promoter, c*ZPR1* (1--780)          This study
  pMM48         p413ADH with *GFP*                                    This study
  pMM49         p413ADH with c*ZPR1*, *GFP*                           This study
  pZPP          pGEX-3X with p*ZPR1*                                  This study
  pLZM1--7      pGEX-5X-1 with m*ZPR1* (fragments 1--7)               [@B12]
  pZM2          pCDNA3 with Flag-m*ZPR1*                              [@B12]
  pZPM          pGEX-3X with m*ZPR1*                                  [@B12]

###### 

Saccharomyces cerevisiae Strains

  Strain      Genotype                                                                                                                        Source
  -------- -- ---------------------------------------------------------------------------------------------------------------------------- -- --------------------------------------------------------------------------
  L40         *MAT* **a** his3Δ200 trp1-901 leu2-3,112 ade2 LYS2:: (lexAop)~4~-His URA3::(lexAop)~8~-LacZ                                     [@B31]
  CY246       *MAT* **a**/MATα lys2-801/lys2-801 ade2-101/ade2-101 leu2-Δ1/leu2-Δ1 his3-Δ200/his3-Δ200 ura3-Δ99/ura3-Δ99                      C.L. Peterson, University of Massachusetts Medical School, Worcester, MA
  MY2         *MAT* **a**/MATα lys2-801/lys2-801 ade2-101/ade2-101 leu2-Δ1/leu2-Δ1/his3-Δ200/his3-Δ200 ura3-Δ99/ura3-Δ99 zpr1::LEU2/ZPR1      This study
  MY7         *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pMM13                                                       This study
  MY28        *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pMM49                                                       This study
  LY1         *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pLC1                                                        This study
  LY2         *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pLCD1                                                       This study
  LY3         *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pLCD2                                                       This study
  LY4         *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pLCD3                                                       This study
  LY5         *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pLCD4                                                       This study
  LY6         *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pLCD5                                                       This study
  LY7         *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pLCD3, pMM38                                                This study
  LY8         *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pLCD5, pMM38                                                This study
  LY9         *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pLCCT                                                       This study
  LY10        *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pLCCT, pMM38                                                This study
  LY11        *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pLCG1                                                       This study
  LY12        *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pMM13, pLCG2                                                This study
  LY13        *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pLCCT2, pLCNT2                                              This study
  LY14        *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pLCG3, pMM38                                                This study
  MY17        *MAT* **a** lys2-801 ade2-101 leu2-Δ1 his3-Δ200 ura3-Δ99 zpr1::LEU2 pMM36                                                       This study

###### 

Identification of ZPR1 homologues in mammals and yeast. (*A*) The sequence of the *S*. *cerevisiae*, *S*. *pombe*, and mouse ZPR1 proteins deduced from the nucleotide sequence of DNA clones is presented. Residues identical to the sequence of mouse ZPR1 are indicated with a period (*.*). Gaps were introduced into the sequences to optimize the alignment (*-*). *Overline*, zinc fingers; *asterisks*, Cys residues. The sequences of mouse *ZPR1*, *S*. *pombe zpr1* and *S*. *cerevisiae ZPR1* have been deposited with GenBank/EMBL/DDBJ accession numbers [U41287](U41287), [AF019768](AF019768) and [AF019769](AF019769), respectively. (*B*) Schematic representation of the predicted domain structure of ZPR1. The regions required for interaction with the EGF receptor are indicated (*EGF-R*).
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###### 

*ZPR1* is an essential gene in the yeast *S*. *cerevisiae*. (*A*) The *S*. *cerevisiae* diploid WT strain (CY246) was used to create the heterozygous strain MY2 (*ZPR1/zpr1::LEU2*). The structures of the wild-type and disrupted c*ZPR1* genes are illustrated. (*B*) Disruption of one *ZPR1* allele was confirmed by Southern blot analysis of PvuI restricted genomic DNA isolated from the diploid WT strain CY246 and the heterozygous strain MY2 (*ZPR1/zpr1::LEU2*). (*C*) The heterozygous diploid strain MY2 (*ZPR1/zpr1::LEU2*) was sporulated and eight randomly selected asci were dissected and examined for viability on YEPD agar media.
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###### 

ZPR1 binds to eEF-1α in vitro. (*A*) A431 cells were labeled with \[^35^S\]methionine. Soluble extracts were prepared and incubated with immobilized ZPR1 (GST--ZPR1) proteins from three species: *S*. *cerevisiae*, *S*. *pombe*, and mouse. Bound proteins were examined by SDS-PAGE and autoradiography. *Arrows*, binding of the 180-kD EGF receptor to mouse ZPR1 and the prominent 50-kD protein that binds to mouse and yeast ZPR1 proteins. (*B*) Deletion analysis of mZPR1 sequences required for interaction with eEF-1α. Immobilized GST and GST--mZPR1 fusion proteins were incubated with cell lysates. Bound eEF-1α was detected by protein immunoblot analysis using a monoclonal antibody to eEF-1α. The binding of eEF-1α to full-length (lane *8*) and truncated (lanes *1--7*) mZPR1 proteins is presented. The mZPR1 amino acid residues in the truncated constructs are: 1--99 (*1*); 94--268 (*2*); 263--306 (*3*); 302--469 (*4*); 1--268 (*5*); 263--469 (*6*); 1--306 (*7*); and 1--469 (*8*). (*C*) Recombinant eEF-1α binds to mZPR1 in vitro. Immobilized GST and GST--eEF-1α were incubated with cell lysates. Bound mZPR1 was detected by protein immunoblot analysis using a rabbit polyclonal antibody to mZPR1. The multiple bands are characteristic of the electrophoretic mobility of mZPR1 ([@B12]). (*D*) Binding of recombinant eEF-1α and cZPR1. Immobilized GST and GST--eEF-1α were incubated with purified CBP--cZPR1. Bound cZPR1 was detected by protein immunoblot analysis.
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Identification of the 50-kD ZPR1-binding Protein by Mass Spectroscopy

  Mass submitted                  Mass matched      Peptide sequences                            Protein matched
  ---------------------------- -- -------------- -- ----------------------------------------- -- ---------------------
  *Saccharomyces cerevisiae*                                                                     
   1026.0000                      1026.2286         \(K\) IGGIGTVPVGR (V)                        
  1494.0000                       1492.7675         \(K\) YAWVLDKLKAER (E)                       
  1563.0000                       1561.7876         \(K\) SHINVVVIGHVDSGK (S)                    
  1861.0000                       1860.1303         \(K\) YQVTVIDAPGHRDFIK (N)                   
  2326.0000                       2326.7513         \(K\) FVPSKPMCVEAFSEYPPLGR (F)               eEF-1α (50032.9 kD)
  2365.0000                       2364.7137         \(K\) TLLEAIDAIEQPSRPTDKKPLR (L)             
  2432.0000                       2431.9076         \(R\) VETGVIKPGMVVTFAPAGVTTEVK (S)           
  2552.0000                       2551.8068         \(K\) SVEMHHEQLEQGVPGDNVGFNVK (N)            
  2911.0000                       2910.2887         \(K\) TVPFVPISGWNGDNMIEATTNAPWYK (G)         
  3320.0000                       3321.8552         \(K\) TLLEAIDAIEQPSRPTDKPLRLPLQDVYK (I)      
                                                                                                 
  Human                                                                                          
    815.6000                       816.9392         \(K\) EKIDRR (S)                             
   959.0000                        960.1287         \(K\) IDRRSGKK (L)                           
   959.0000                        960.1256         \(K\) SAQKAQKAK (--)                         
  1026.0000                       1026.2286         \(K\) IGGIGTVPVGR (V)                        
  1121.0000                       1121.2830         \(K\) STTTGHLIYK (C)                         eEF-1α (50127.1 kD)
  1315.5000                       1314.5320         \(K\) GSFKYAWVLDK (L)                        
  1315.5000                       1315.5608         \(R\) EHALLAYTLGVK (Q)                       
  1405.8000                       1405.6019         \(K\) YYVTIIDAPGHR (D)                       
  1405.8000                       1405.6461         \(K\) FAELKEKIDRR (S)                        
  1590.3000                       1589.8416         \(K\) THINIVVIGHVDSGK (S)                    
  2517.6001                       2517.0136         \(R\) VETGVLKPGMVVTFAPVNVTTEVK (S)           
  3011.8000                       3011.4769         \(R\) KSGDAIVDMVPGKPMCVESPSDYPPLGR (F)       

The 50-kD protein was purified by affinity chromatography and SDS-PAGE. The protein was electroblotted onto a PVDF membrane, digested with [l]{.smallcaps}-tosylamido-2-phenyl ethyl chloromethyl ketone-treated trypsin, and then subjected to mass spectroscopy using the MALDI-TOF technique. Peptide masses obtained were compared with the MS-Fit database.  

![Coimmunoprecipitation analysis demonstrates that eEF-1α and ZPR1 interact in vivo. (*A*) COS-7 cells were mock-transfected (*CONTROL*) or transfected with a vector expressing epitope-tagged ZPR1. Flag-ZPR1 was immunoprecipitated with the M2 monoclonal antibody. eEF-1α in the immunoprecipitates (*IP*) was detected by protein immunoblot analysis with a monoclonal antibody to eEF-1α. (*B*) Coimmunoprecipitation of ZPR1 with eEF-1α from cells treated with serum or EGF. A431 epidermoid carcinoma cells were incubated in serum-free medium for 24 h. The cells were untreated or treated with 5% calf serum, 100 nM EGF, or 100 nM PMA for 15 min. Extracts were prepared from the cells and eEF-1α was isolated by immunoprecipitation. Specificity of the immunoprecipitation was examined using mock immunoprecipitates prepared using protein A--Sepharose beads without antibody to eEF-1α (*CONTROL*). ZPR1 in the immunoprecipitates was detected by protein immunoblot analysis using a rabbit polyclonal antibody. (*C*) EGF causes the rapid formation of ZPR1/eEF-1α complexes that are detected by coimmunoprecipitation analysis. A431 cells were serum starved for 24 h. The cells were incubated with 100 nM EGF for various times, extracts were prepared, and then eEF-1α was isolated by immunoprecipitation. Specificity of the immunoprecipitation was examined using mock immunoprecipitates prepared using protein A--Sepharose beads without antibody to eEF-1α (*CONTROL*). The presence of ZPR1 in the immunoprecipitates was examined by protein immunoblot analysis with a rabbit polyclonal antibody.](JCB9807048.f4){#F4}

![Redistribution of eEF-1α and ZPR1 from the cytoplasm to the nucleus in EGF-treated cells. A431 cells were incubated in serum-free medium for 24 h (starved) and then treated with 100 nM EGF or 100 nM PMA for 15 min at 37°C. The cells were fixed, permeabilized, and then examined by double-label immunofluorescence microscopy. Fluorescein (*green*) and cyanine (*red*) represent eEF-1α and ZPR1, respectively. *Yellow*, colocalization of eEF-1α and ZPR1 in the nucleus upon EGF treatment in merged images. Bar, 50 μm.](JCB9807048.f5){#F5}

![Redistribution of ZPR1 in the yeast *S*. *cerevisiae*. The haploid yeast strain MY28 (Table [III](#TIII){ref-type="table"}) examined by fluorescence microscopy. This yeast strain expresses cZPR1--GFP in the absence of wild-type cZPR1. The cells were grown in synthetic medium with glucose (*CONTROL*) and starved in glucose-free medium for 12 h (*STARVED*). Glucose (2%) was added to the starved cells and incubated for 2 h (*GLUCOSE*). The GFP (*green*) and DAPI (*blue*) represents ZPR1 and DNA, respectively. Bar, 10 μm.](JCB9807048.f6){#F6}

###### 

A small region of ZPR1 is required for interaction with eEF-1α in the yeast *S*. *cerevisiae*. (*A*) Schematic representation of *S*. *cerevisiae* ZPR1. NH~2~-terminal (*NT*; residues 1--261) and COOH-terminal (*CT*; residues 262--486) fragments of cZPR1 are illustrated. In-frame deletions within the full-length cZPR1 protein were constructed: D1 (residues 222--241), D2 (residues 222-- 261), D3 (residues 202--241), D4 (residues 202--261), and D5 (residues 202--221). The sequence of the D5 region in mouse and yeast ZPR1 proteins is illustrated. (*B--D*) Recombinant cZPR1 proteins were expressed as a CBP fusion protein in bacteria. The CBP fusion proteins were purified, immobilized, and then used for binding assays using cell lysates. Bound eEF-1α was detected by protein immunoblot analysis. The binding of eEF-1α to NT and CT fragments of cZPR1 was examined (*B*). The effect of in-frame deletions (*D1*, *D2*, *D3*, and *D4*) of cZPR1 was investigated (*C*). The effect of the D5 in-frame deletion mutation of cZPR1 was also examined (*D*).
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###### 

Mutational Analysis of the Effect of ZPR1 on Yeast Viability and the Interaction of ZPR1 with eEF-1α

  *ZPR1*                      Complementation      eEF-1α binding
  ------------------------ -- ----------------- -- ----------------
  Empty plasmid p413 ADH      −                    −
  WT                          \+                   \+
  D1                          \+                   \+
  D2                          \+                   \+
  D3                          \+                   −
  D3 + NT                     \+                   \+
  D5                          \+                   −
  D5 + NT                     \+                   \+
  NT                          −                    \+
  CT                          \+                   −
  CT + NT                     \+                   \+
  CT + NT (ΔD5)               \+                   −
  MtZnF1                      \+                   \+
  MtZnF2                      −                    \+

Viability of haploid yeast (*zpr1::LEU2*) transformed with plasmid expression vectors for wild-type and mutated ZPR1 proteins was scored as positive (+) or negative (−). Binding of recombinant ZPR1 to eEF-1α was detected in vitro (+, −).  

###### 

Mutational analysis of the effect of ZPR1 on the growth of the yeast *S*. *cerevisiae*. (*A*) The growth of haploid yeast strains (*zpr1::LEU2*) complemented with plasmid expression vectors for wild-type (*WT*) and mutated (*D1*, *D2*, *D3*, *D5*, and *NT*) c*ZPR1* was examined. Liquid cultures of the yeast (0.2 OD~600~) were serially diluted to 5-, 10-, 50-, 100- and 1,000-fold, spotted onto YEPD plates, and then incubated at 30°C. (*B*) The growth of haploid yeast strains (*zpr1::LEU2*) complemented with plasmid expression vectors for wild-type (*WT*) and mutated (*CT*, *NT*, and *NTΔD5*) c*ZPR1* was examined as described above. (*C*) Morphology of haploid yeast strains (*zpr1::LEU2*) complemented with plasmid expression vectors for WT cZPR1 (strain LY1) and mutant D5 cZPR1 (strain LY6) was examined by microscopy using Nomarski optics. DNA was detected by DAPI staining and fluorescence microscopy. (*D*) FACS^®^ analysis of the haploid yeast strains LY1 and LY6 expressing wild-type and mutant (*D5*) cZPR1, respectively. (*E*) Mutational analysis of the sub-cellular localization of cZPR1 in *S*. *cerevisiae*. The location of wild-type cZPR1 (*cZPR1-GFP*), D5 mutant cZPR1 (*D5-GFP*), the NT fragment of cZPR1 (*NT-GFP*), and the CT fragment of cZPR1 (*CT-GFP*) was examined by fluorescence microscopy of yeast strains MY28, LY11, LY12, and LY14, respectively (Table [II](#TII){ref-type="table"}). Bars: (*C*) 50 μm; (*E*) 10 μm.
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